Finch Therapeutics Group (FNCH) Expected to Announce Quarterly Earnings on Friday

Finch Therapeutics Group (NASDAQ:FNCH) is projected to post its resultson Friday, March 27th. Analysts expect Finch Therapeutics Group to post earnings of ($30.00) per share and revenue of $3.60 million for the quarter.

Finch Therapeutics Group Price Performance

Shares of NASDAQ FNCH opened at $7.30 on Thursday. The stock has a market capitalization of $11.72 million, a price-to-earnings ratio of -0.83 and a beta of 1.18. The stock’s fifty day simple moving average is $13.01 and its 200 day simple moving average is $13.11. Finch Therapeutics Group has a 52-week low of $2.00 and a 52-week high of $16.10.

About Finch Therapeutics Group

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.